LS Investment Advisors’s Myriad Genetics MYGN Stock Holding History

LS Investment Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,523	Closed	-$29K	–	1200
2020 Q2	$29K	Hold	2,523	–	–	﹤0.01%	1304
2020 Q1	$36K	Hold	2,523	–	–	﹤0.01%	1197
2019 Q4	$69K	Hold	2,523	–	–	﹤0.01%	1238
2019 Q3	$72K	Hold	2,523	–	–	﹤0.01%	1185
2019 Q2	$70K	Hold	2,523	–	–	﹤0.01%	1207
2019 Q1	$84K	Hold	2,523	–	–	0.01%	1131
2018 Q4	$73K	Sell	2,523 -1,701	-40%	-$61.2K	0.01%	1161
2018 Q3	$194K	Sell	4,224 -707	-14%	-$31.4K	0.01%	863
2018 Q2	$184K	Buy	4,931 +57	+1%	+$1.93K	0.01%	907
2018 Q1	$144K	Buy	4,874 +83	+2%	+$2.81K	0.01%	995
2017 Q4	$165K	Buy	4,791 +2,250	+89%	+$75.9K	0.01%	994
2017 Q3	$92K	Sell	2,541 -334	-12%	-$9.53K	0.01%	1176
2017 Q2	$74K	Hold	2,875	–	–	﹤0.01%	1235
2017 Q1	$55K	Buy	+2,875	New	+$50.9K	﹤0.01%	1303

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LS Investment Advisors's MYGN Position: Q3 2020 in Review

LS Investment Advisors sold out of Myriad Genetics (MYGN) in Q3 2020, closing a stake of 2,523 shares — an estimated $29K sold.

LS Investment Advisors first reported a position in MYGN in Q1 2017 and held it in 14 quarters. The position peaked at $194K in Q3 2018. 192 funds tracked by Wall St. Rank hold MYGN as of Q3 2020.

LS Investment Advisors reported no remaining Myriad Genetics position as of Q3 2020 after selling out during the quarter.
LS Investment Advisors sold 2,523 Myriad Genetics shares in Q3 2020, an estimated $29K.
LS Investment Advisors first reported a position in Myriad Genetics in Q1 2017 and held it in 14 quarters.
LS Investment Advisors's Myriad Genetics position peaked at $194K in Q3 2018.
192 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2020.

Based on LS Investment Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.